Draft — DayOne Accelerator Program

MOTIVATION LETTER

The DayOne Accelerator Program targets early-stage healthtech ventures with a clear path to pharma R&D integration. My venture, built on the Conjunctive Consolidation Threshold (CCT) model, delivers exactly that: a validated computational pharmacology platform that reduces reward-memory encoding probability from 0.855 to 0.122, an 85.8 percent reduction confirmed across five pre-registered hypotheses H1 through H5. The CCT model is a tripartite pharmacological framework for addiction-liability screening, and the IMPRINT platform operationalizes it for scalable deployment. A provisional patent on the core architecture is filed for Q3 2026. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU anchor the scientific credibility of this work. The DayOne program's focus on early-stage, high-impact healthtech aligns precisely with my pre-seed stage, provisional patent status, and validated clinical trial architecture. I am applying to accelerate the transition from mathematical proof to commercial screening tool for pharmaceutical pipelines.

SHORT ESSAY: INNOVATION AND SCIENTIFIC MERIT

The CCT model introduces a conjunctive consolidation threshold that integrates dopamine D1 receptor antagonism, NMDA receptor antagonism, and protein synthesis inhibition at a specific temporal window. This is a new pharmacological principle, not a repurposing of existing compounds. The formal mathematical specification, published on OSF (10.17605/OSF.IO/EMY4U), uses ODE/RK45 solvers and Bayesian MCMC validation. The Bayesian population dynamics paper on Zenodo (10.5281/zenodo.20492472) demonstrates super-additivity of 12.8 percentage points, meaning the combined effect exceeds the sum of individual drug effects. This super-additivity is the mechanistic novelty that makes the CCT model patentable and commercially distinct. The review article under review at Neuroscience and Biobehavioral Reviews provides the field-level context. No existing addiction-liability screening tool uses this mechanism.

SHORT ESSAY: MARKET POTENTIAL AND SCALABILITY

Pharmaceutical companies spend an estimated 2.5 billion dollars per drug development cycle. Addiction liability is a major cause of post-market withdrawal and regulatory delay. The IMPRINT platform screens candidate compounds for addiction liability using the CCT model's encoding probability metric. A single screening run costs less than 500 dollars in computational resources. The addressable market includes every CNS drug development program in the top 20 pharma companies. The platform scales horizontally on HPC clusters using Nextflow and SLURM, and the codebase is Apache 2.0 licensed for transparency. The clinical trial architecture specified in the Zenodo paper provides a clear regulatory pathway. Revenue model: per-screening fee plus annual enterprise license for pipeline integration.

SHORT ESSAY: FOUNDING TEAM AND EXPERTISE

I am Eniola Ayodele Olutogun, a licensed pharmacist (B.Pharm, University of Ibadan, CGPA 5.1/7.0, German equivalent 1.9) with independent research output of three sole-authored preprints, one review article under review, and one co-authored paper under review at Alcohol (Elsevier). I built three platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation. My technical stack includes Python (scipy, numpy, PyMC, ODE/RK45), R, TDA libraries (Ripser, Gudhi), NEURON/Brian2, AlphaFold, RDKit, ADMET/QSAR, GROMACS, AutoDock, and Nextflow/SLURM/HPC. I currently serve as National Product Manager at Synthcare, managing product strategy across Nigeria. The endorsements from Berridge, Gershman, Daw, and Mattar provide advisory depth without requiring co-founder equity.

SHORT ESSAY: STAGE OF DEVELOPMENT

The venture is pre-seed. The CCT model is mathematically validated. The IMPRINT platform is built and functional. The provisional patent is filed for Q3 2026. The clinical trial architecture is specified. The next milestone is a pilot validation study with a partner pharmaceutical company, targeting three known addictive compounds and three non-addictive controls. This pilot requires 50,000 dollars for computational resources, data analysis, and regulatory consultation. The DayOne Accelerator provides the mentorship and network to secure that partnership. The program's emphasis on early-stage ventures matches my current stage: validated science, built platform, no revenue yet, clear path to first customer.

SHORT ESSAY: ALIGNMENT WITH DAYONE FOCUS

DayOne Accelerator targets healthtech and pharma R&D ventures. My venture sits at the intersection of computational neuroscience and pharmaceutical screening. The CCT model addresses a specific, costly problem in drug development: addiction liability. The IMPRINT platform delivers a quantitative answer in hours instead of months. The program's European base is relevant because my MSc application targets Medical University of Graz in Austria for an October 2026 start, and the venture can operate from Graz as a base for EU pharma partnerships. The lack of a specific funding amount in the program description is not a barrier; the mentorship and network are the primary value at this stage.

CHECKLIST

- [ ] Complete online application form at DayOne Accelerator website
- [ ] Upload pitch deck (10-12 slides) covering CCT model, IMPRINT platform, market analysis, team, financial projections
- [ ] Upload one-page executive summary
- [ ] Provide links to OSF preprints (10.17605/OSF.IO/KG7B5, 10.17605/OSF.IO/EMY4U) and Zenodo paper (10.5281/zenodo.20492472)
- [ ] Provide link to IMPRINT platform repository or demo
- [ ] Provide link to provisional patent filing number (Q3 2026)
- [ ] Provide endorsement letters or contact information for Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar
- [ ] Confirm eligibility for early-stage, pre-revenue ventures
- [ ] Confirm no conflict with MSc application timeline (October 2026 start)

EDITOR NOTES

- Eligibility risk: DayOne Accelerator may require a registered company entity. Confirm whether a sole proprietorship or Nigerian business registration is sufficient, or if EU incorporation is needed before application.
- Fact verification: Confirm that the provisional patent filing is accepted and has a filing number. The profile states Q3 2026, which may be future-dated. Verify current status.
- Gap: The profile does not specify the exact name of the venture entity. Insert the legal name of the company or project under which the CCT model and IMPRINT platform are being commercialized.

MOTIVATION LETTER

The DayOne Accelerator Program targets early-stage healthtech ventures with a clear path to pharma R&D integration. My venture, built on the Conjunctive Consolidation Threshold (CCT) model, delivers exactly that: a validated computational pharmacology platform that reduces reward-memory encoding probability from 0.855 to 0.122, an 85.8 percent reduction confirmed across five pre-registered hypotheses H1 through H5. The CCT model is a tripartite pharmacological framework for addiction-liability screening, and the IMPRINT platform operationalizes it for scalable deployment. A provisional patent on the core architecture is filed for Q3 2026. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU anchor the scientific credibility of this work. The DayOne program's focus on early-stage, high-impact healthtech aligns precisely with my pre-seed stage, provisional patent status, and validated clinical trial architecture. I am applying to accelerate the transition from mathematical proof to commercial screening tool for pharmaceutical pipelines.

SHORT ESSAY: INNOVATION AND SCIENTIFIC MERIT

The CCT model introduces a conjunctive consolidation threshold that integrates dopamine D1 receptor antagonism, NMDA receptor antagonism, and protein synthesis inhibition at a specific temporal window. This is a new pharmacological principle, not a repurposing of existing compounds. The formal mathematical specification, published on OSF (10.17605/OSF.IO/EMY4U), uses ODE/RK45 solvers and Bayesian MCMC validation. The Bayesian population dynamics paper on Zenodo (10.5281/zenodo.20492472) demonstrates super-additivity of 12.8 percentage points, meaning the combined effect exceeds the sum of individual drug effects. This super-additivity is the mechanistic novelty that makes the CCT model patentable and commercially distinct. The review article under review at Neuroscience and Biobehavioral Reviews provides the field-level context. No existing addiction-liability screening tool uses this mechanism.

SHORT ESSAY: MARKET POTENTIAL AND SCALABILITY

Pharmaceutical companies spend an estimated 2.5 billion dollars per drug development cycle. Addiction liability is a major cause of post-market withdrawal and regulatory delay. The IMPRINT platform screens candidate compounds for addiction liability using the CCT model's encoding probability metric. A single screening run costs less than 500 dollars in computational resources. The addressable market includes every CNS drug development program in the top 20 pharma companies. The platform scales horizontally on HPC clusters using Nextflow and SLURM, and the codebase is Apache 2.0 licensed for transparency. The clinical trial architecture specified in the Zenodo paper provides a clear regulatory pathway. Revenue model: per-screening fee plus annual enterprise license for pipeline integration.

SHORT ESSAY: FOUNDING TEAM AND EXPERTISE

I am Eniola Ayodele Olutogun, a licensed pharmacist (B.Pharm, University of Ibadan, CGPA 5.1/7.0, German equivalent 1.9) with independent research output of three sole-authored preprints, one review article under review, and one co-authored paper under review at Alcohol (Elsevier). I built three platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation. My technical stack includes Python (scipy, numpy, PyMC, ODE/RK45), R, TDA libraries (Ripser, Gudhi), NEURON/Brian2, AlphaFold, RDKit, ADMET/QSAR, GROMACS, AutoDock, and Nextflow/SLURM/HPC. I currently serve as National Product Manager at Synthcare, managing product strategy across Nigeria. The endorsements from Berridge, Gershman, Daw, and Mattar provide advisory depth without requiring co-founder equity.

SHORT ESSAY: STAGE OF DEVELOPMENT

The venture is pre-seed. The CCT model is mathematically validated. The IMPRINT platform is built and functional. The provisional patent is filed for Q3 2026. The clinical trial architecture is specified. The next milestone is a pilot validation study with a partner pharmaceutical company, targeting three known addictive compounds and three non-addictive controls. This pilot requires 50,000 dollars for computational resources, data analysis, and regulatory consultation. The DayOne Accelerator provides the mentorship and network to secure that partnership. The program's emphasis on early-stage ventures matches my current stage: validated science, built platform, no revenue yet, clear path to first customer.

SHORT ESSAY: ALIGNMENT WITH DAYONE FOCUS

DayOne Accelerator targets healthtech and pharma R&D ventures. My venture sits at the intersection of computational neuroscience and pharmaceutical screening. The CCT model addresses a specific, costly problem in drug development: addiction liability. The IMPRINT platform delivers a quantitative answer in hours instead of months. The program's European base is relevant because my MSc application targets Medical University of Graz in Austria for an October 2026 start, and the venture can operate from Graz as a base for EU pharma partnerships. The lack of a specific funding amount in the program description is not a barrier; the mentorship and network are the primary value at this stage.

CHECKLIST

- [ ] Complete online application form at DayOne Accelerator website
- [ ] Upload pitch deck (10-12 slides) covering CCT model, IMPRINT platform, market analysis, team, financial projections
- [ ] Upload one-page executive summary
- [ ] Provide links to OSF preprints (10.17605/OSF.IO/KG7B5, 10.17605/OSF.IO/EMY4U) and Zenodo paper (10.5281/zenodo.20492472)
- [ ] Provide link to IMPRINT platform repository or demo
- [ ] Provide link to provisional patent filing number (Q3 2026)
- [ ] Provide endorsement letters or contact information for Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar
- [ ] Confirm eligibility for early-stage, pre-revenue ventures
- [ ] Confirm no conflict with MSc application timeline (October 2026 start)

EDITOR NOTES

- Eligibility risk: DayOne Accelerator may require a registered company entity. Confirm whether a sole proprietorship or Nigerian business registration is sufficient, or if EU incorporation is needed before application.
- Fact verification: Confirm that the provisional patent filing is accepted and has a filing number. The profile states Q3 2026, which may be future-dated. Verify current status.
- Gap: The profile does not specify the exact name of the venture entity. Insert the legal name of the company or project under which the CCT model and IMPRINT platform are being commercialized.

AI Draft — DayOne Accelerator Program